News

Filter

Current filters:

Regulus Therapeutics

Sanofi renews alliance with Regulus and ups investment by $10 million

Sanofi renews alliance with Regulus and ups investment by $10 million

05-02-2014

US pharma company Regulus Therapeutics has renewed its strategic alliance with French drug major Sanofi…

FinancialFranceOncologyPharmaceuticalRare diseasesRegulus TherapeuticsResearchSanofiUSA

AstraZeneca aligns with Regulus for microRNA therapeutics

16-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

Sanofi-Aventis expands into microRNA sector in up to $750 million deal with Regulus

23-06-2010

French drug major Sanofi-Aventis has increased its research interest into the microRNA sector, signing…

Alnylam PharmaceuticalsIsis PharmaceuticalsLicensingPharmaceuticalRegulus TherapeuticsResearchSanofi-Aventis

Regulus raises $20M

16-03-2009

Regulus Therapeutics, which was formed in 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals, has…

Alnylam PharmaceuticalsGlaxoSmithKlineGSKIsis PharmaceuticalsRegulus Therapeutics

Rosetta Genomics transfers project with Isis to Regulus

29-09-2008

Rosetta Genomics, a US firm specializing on the development of microRNA-based diagnostics and therapeutics,…

Regulus Therapeutics

Role for miR-21 in regulating certain cancer cells

01-09-2008

Regulus Therapeutics, a joint venture between US RNAi specialists Alnylam and Isis, say that new data…

Regulus Therapeutics

Mega drug licensing deal with GSK could bring Regulus Thereapeutics $600M

28-04-2008

Moving to boost its biotechnology portfolio, UK-headquartered drugs giant GlaxoSmithKline has entered…

Drug DiscoveryGlaxoSmithKlineGSKIsis PharmaceuticalsRegulus Therapeutics

Alnylam and Isis form Regulus Thera JV

17-09-2007

RNAi therapeutics specialist Alnylam Pharmaceuticals and fellow USA-based firm Isis Pharmaceuticals have…

Alnylam PharmaceuticalsIsis PharmaceuticalsRegulus Therapeutics

COMPANY SPOTLIGHT

Menarini

Back to top